MONTOMOLI, EMANUELE
 Distribuzione geografica
Continente #
EU - Europa 11.015
NA - Nord America 9.339
AS - Asia 1.516
AF - Africa 58
OC - Oceania 14
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 21.960
Nazione #
US - Stati Uniti d'America 9.302
GB - Regno Unito 4.810
IE - Irlanda 1.754
IT - Italia 1.035
CN - Cina 929
UA - Ucraina 811
SE - Svezia 753
RU - Federazione Russa 547
FR - Francia 472
DE - Germania 386
SG - Singapore 278
FI - Finlandia 267
VN - Vietnam 191
CI - Costa d'Avorio 46
ES - Italia 38
BE - Belgio 33
CA - Canada 26
TR - Turchia 22
IN - India 19
KR - Corea 19
CZ - Repubblica Ceca 17
NL - Olanda 15
AU - Australia 11
AT - Austria 10
IR - Iran 7
JP - Giappone 7
BG - Bulgaria 6
BR - Brasile 6
PL - Polonia 6
CH - Svizzera 5
DK - Danimarca 5
GR - Grecia 5
HK - Hong Kong 5
LU - Lussemburgo 5
MX - Messico 5
AM - Armenia 4
EU - Europa 4
HU - Ungheria 4
KG - Kirghizistan 4
MA - Marocco 4
PH - Filippine 4
RO - Romania 4
EG - Egitto 3
ID - Indonesia 3
IL - Israele 3
LT - Lituania 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PE - Perù 3
ZA - Sudafrica 3
AL - Albania 2
AR - Argentina 2
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
HR - Croazia 2
JM - Giamaica 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
SC - Seychelles 2
TW - Taiwan 2
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GL - Groenlandia 1
IM - Isola di Man 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
OM - Oman 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TJ - Tagikistan 1
TM - Turkmenistan 1
Totale 21.960
Città #
Southend 4.623
Dublin 1.738
Fairfield 1.471
Chandler 987
Ashburn 745
Woodbridge 710
Jacksonville 681
Houston 590
Wilmington 566
Seattle 552
Cambridge 470
Ann Arbor 406
Siena 374
Princeton 282
Nanjing 229
Dong Ket 189
Singapore 187
Beijing 166
San Mateo 118
San Diego 113
Boardman 112
Helsinki 112
Moscow 74
Nanchang 74
Shenyang 52
Shanghai 50
Tianjin 47
Abidjan 46
Florence 45
Hebei 42
Lappeenranta 42
Rome 40
Málaga 37
Kunming 34
Brussels 32
Jiaxing 32
Milan 32
London 29
Munich 29
New York 28
Norwalk 28
Dearborn 25
Changsha 24
Hangzhou 24
Jinan 23
Redwood City 20
Phoenix 18
Lancaster 17
Ningbo 17
Toronto 17
Genova 16
Los Angeles 15
Fremont 14
San Francisco 14
Santa Clara 14
Brno 13
Livorno 13
Taizhou 13
Zhengzhou 12
Guangzhou 11
Izmir 11
Auburn Hills 9
Fuzhou 9
Vienna 9
Bari 8
Changchun 8
Düsseldorf 8
Roccagorga 8
Amsterdam 7
Bologna 7
Dessau 7
Washington 7
Chicago 6
Frankfurt am Main 6
Hounslow 6
Kilburn 6
Lanzhou 6
Melbourne 6
Mestre 6
Parma 6
Philadelphia 6
Stockholm 6
Torre Del Greco 6
Agliana 5
Dallas 5
Luxembourg 5
Mumbai 5
Naples 5
Pisa 5
Prescot 5
Renton 5
Venezia 5
Andover 4
Atlanta 4
Bishkek 4
Brescia 4
Budapest 4
Cagliari 4
Carmignano 4
Copenhagen 4
Totale 16.775
Nome #
A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses 498
Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014 458
How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions 456
Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains 431
Toxoplasma gondii in women of childbearing age and during pregnancy: seroprevalence study in Central and Southern Italy from 2013 to 2017 399
Elimination of congenital rubella: a seroprevalence study of pregnant women and women of childbearing age in Italy 392
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe: Results from the I-MOVE+ project 378
Pertussis over two decades: Seroepidemiological study in a large population of the Siena Province, Tuscany Region, Central Italy 350
Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice 223
Egg-Independent Influenza Vaccines and Vaccine Candidates 217
Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2 209
Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children 188
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 186
Flucelvax (Optaflu) for seasonal influenza 185
Moderate vaccine effectiveness against severe acute respiratory infection caused by a(H1N1)pdm09 influenza virus and no effectiveness against a(H3N2) influenza virus in the 2018/2019 season in Italy 185
Influenza immunology evaluation and correlates of protection: a focus on vaccines 183
Influenza anti-stalk antibodies: Development of a new method for the evaluation of the immune responses to universal vaccine 183
Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination 172
A method for detection of neuraminidase antibody in serum 171
Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season 171
Emerging influenza strains in the last two decades: A threat of a new pandemic? 169
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 168
Influenza D virus: Serological evidence in the Italian population from 2005 to 2017 160
Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention 155
Challenges in the development of egg-independent vaccines for influenza 153
Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses 152
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: Awareness warranted for 2017/18 season 152
Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans 149
Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production 148
Retrospective Study Evaluating Seroprevalence of Hepatitis E Virus in Blood Donors and in Swine Veterinarians in Italy (2004) 147
Neisseria meningitidis infection: Who, when and where? 147
Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine vaxigrip tetra: Preliminary results in children ≥6 months and older adults 146
Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines 145
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine 144
How much ozone bactericidal activity is compromised by plasma components? 143
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies 142
Influenza vaccines: Evaluation of the safety profile 142
Impact of erythrocyte species on assays for influenza serology 141
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza 141
N. meningitidis and TLR polymorphisms: A fascinating immunomodulatory network 140
Age and influenza-specific pre-vaccination antibodies strongly affect influenza vaccine responses in the icelandic population whereas disease and medication have small effects 139
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice 137
Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention 136
null 136
RT-PCR multiplex per l’identificazione simultanea di influenza virus A/H1N1 A/H3N2 e B e Virus Respiratorio Sinciziale di tipo A e B 134
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies 133
A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines 132
An unwanted guest: Neisseria meningitidis–carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence 132
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture 132
Live attenuated influenza vaccine in children induces b-cell responses in tonsils 131
Fighting Neisseria meningitidis: past and current vaccination strategies 131
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses 130
null 130
Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection 129
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates 129
Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge 128
A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly. 127
International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE 125
Measles in pregnancy: a threat for Italian women? 125
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 125
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 125
A Cell Culture (Vero)–Derived H5N1 Whole-Virus Vaccine Induces Cross-Reactive Memory Responses 124
Is influenza A/H10N8 a potential candidate for the next pandemic? 122
Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence 121
Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza 121
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 121
Thymosin-alpha 1 (Zadaxin™) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria™) in hemodialyzed patients: A pilot study 120
Cost-benefit evaluation of anti-influenza vaccination in the elderly during two influenza seasons in the Siena district [Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in due stagioni epidemiche a confronto nella provincia di Siena] 120
Susceptibility to varicella in childbearing age women, Central Italy: is there a need for vaccinating this population group? 119
Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) 119
Overview of serological techniques for influenza vaccine evaluation: Past, Present and Future 119
Mapping host-related correlates of influenza vaccine-induced immune response: An umbrella review of the available systematic reviews and meta-analyses 119
Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals 119
Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses 118
Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy 117
The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants 117
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine 117
Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period 117
Understanding the dynamics of seasonal influenza in Italy: incidence, transmissibility and population susceptibility in a 9-year period 116
Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemic 114
Priming for Pandemic Influenza: Antigen-sparing MF59™-adjuvanted A/H5N1 Vaccine Induces Immunological Memory and Shows Cross-Reactive Potential in Adults Including the Elderly 114
Correlates of protection against influenza 112
Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations 112
Safety, tolerability and immunogenicity of a mammalian cell culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial 111
Epidemiologia e prevenzione delle malattie dentali a Siena: studio pluriennale (1988-1996) su campioni di alunni della scuola dell'obbligo. 110
Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy 110
Cross subclade immunity after one-year booster immunization with MF59®-adjuvanted A/H5N1 influenza vaccine in 6 month to 17 year-old children 108
null 108
Expression of sialic acid influenza receptors in red blood cells from avian and mammalian species: an immunological comparative study 107
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in tuscany, Italy 107
Pre-emptive vaccination against pandemic influenza virus 106
Current adjuvants and new perspectives in vaccine formulation 105
Vaccination against Hepatitis B - Lenght of protection among populations at risk 103
Low prevalence of antibodies against pertussis in pregnant women in Italy 103
Immunity to measles in Italian children and adolescents: a persistent problem in view of measles elimination 103
Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples 103
Correlates of protection against influenza 100
Medicine use and recurrent complaints among 15-years-old adolescents in Tuscany 100
Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains 100
The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine 99
Totale 15.746
Categoria #
all - tutte 71.534
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.534


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.107 0 0 282 625 331 388 376 593 422 438 260 392
2020/20214.814 238 431 214 578 376 503 220 565 369 530 359 431
2021/20222.653 236 394 263 233 100 75 115 174 164 214 225 460
2022/20233.333 201 296 402 480 311 666 90 299 344 62 111 71
2023/20242.547 86 75 187 110 101 589 981 75 27 111 38 167
2024/20251.104 160 386 558 0 0 0 0 0 0 0 0 0
Totale 22.349